SHM to collect data on prior PrEP use Read online | Unsubscribe
Stichting HIV Monitoring news
Spring 2019
HIV Monitoring
SHM to collect info on prior PrEP use 
Why do we need to collect information on prior use of pre-exposure prophylaxis (PrEP) among people newly-diagnosed with HIV, and what needs to be done to allow SHM to collect this information?

We spoke to SHM researcher and HIV treating physician, Ferdinand Wit, to find out more.  
Read more

Spotlight on SHM research: venous thromboembolism in people with HIV
The risk of venous thromboembolism is elevated in people with HIV, but approaches that of the general population in those with a normalised immune status, report Dutch researchers in The Lancet HIV.
Read more

(Image: The Lancet HIV, Vol 6, Issue 3, Cover page, © Elsevier 2019)

Meet our new researcher, Anders Boyd
With a broad international background and a strong focus on statistical modelling, Anders Boyd brings new expertise to our research team.

Read on to find out more about Anders and his plans for his work at SHM. 
Read more
NCHIV2019: Registration & abstract submission open 6 May
Join the NCHIV organising committee on 13 November in the KIT in Amsterdam for what promises to be another stimulating edition of NCHIV.

The preliminary programme features talks by a number of distinguished experts in the field of HIV research, including a keynote lecture by Dr. Anthony Fauci of the NIH/NIAID
Read more

SHM's ATHENA data at
CROI 2019

Data from our ATHENA cohort contributed to five posters at CROI 2019 on topics such as children with HIV, integrase inhibitors, comorbidites and congitive impairment.

Click on the button below for a list of the poster titles and authors.

Read more

Recent publications

Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM
This study investigated a non-invasive measure of liver fibrosis, FIB-4, in 313 MSM with hepatitis C. During the acute phase of infection, FIB-4 was transiently elevated. However, three and a half years later, only 8 men had signs of severe liver fibrosis (FIB-4 ≥3.45), while in more than 75% liver fibrosis could be ruled out (FIB-4 <1.45).
» AIDS 2019 Apr 1;33(5):833-844. doi: 10.1097/QAD.0000000000002138.

Determinants of restoration of CD4 and CD8 cell counts and their ratio in HIV-1-positive individuals with sustained virological suppression on antiretroviral therapy 
When combination antiretroviral therapy is started at CD4 cell counts of about 500 cells/mm3, there is a greater chance of the CD4 count reaching normal levels again. However, CD8 cell counts remain elevated compared with HIV-negative individuals, yielding a lower CD4:CD8 ratio. The clinical consequences of this are unclear. 
» J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):292-300. doi: 10.1097/QAI.0000000000001913.

Cost-effectiveness of increased HIV testing among men who have sex with men in the Netherlands
Approximately 20 percent of men who have sex with men who get tested for HIV at an STD clinic, do so every 6 months. More testing could prevent a large number of HIV infections, but is only cost-effective if more testing is carried out amon men with an increased risk of HIV. 
» AIDS 2019 Mar 15. doi: 10.1097/QAD.000000000000219.

Meibergdreef 9
1105 AZ Amsterdam
020 566 41 72
Thanks to
Jaime Borjas-Howard, Anders Boyd, Catriona Ester, Brid Peeck, Peter Reiss, Casper Rokx, Ard van Sighem, Yunka de Waart, Ferdinand Wit. 
Follow us on:
Copyright © 2019 Stichting HIV Monitoring, All rights reserved.